Ankylosing spondylitis
Latest News
Upadacitinib recommended for nonradiographic axSpA in Europe
The Janus kinase inhibitor is already approved for active ankylosing spondylitis in the European Union.
Conference Coverage
Treat-to-target strategy with tapering proves effective in PsA and axSpA
A trial showed for the first time that disease activity–guided treat-to-target tapering strategies in both psoriatic arthritis and axial...
Conference Coverage
Diagnostic axSpA MRI features differ in men and women
The cohort study of German patients with and without the disease found no major sex-specific differences for erosion and bone marrow edema but did...
Conference Coverage
Bimekizumab tames active ankylosing spondylitis in BE MOBILE 2
The dual IL-17A and IL-17F inhibitor improved function, quality of life, and objective measures of inflammation, compared with placebo, in...
Conference Coverage
Upadacitinib effective against nonradiographic AxSpA
The JAK inhibitor was effective and safe for patients with rheumatologist-diagnosed axial spondyloarthritis that did not meet radiographic...
Feature
Abortion debate may affect Rx decisions for pregnant women
Enactment of abortion restrictions in a growing number of states could have a chilling effect on therapy regimens in pregnant women and their...
Conference Coverage
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
Conference Coverage
IBD risk ‘uncertain’ in biologic-treated AxSpA patients
“Enormous uncertainty” surrounds the risk of inflammatory bowel disease associated with biologic treatment in patients with axial...
From the Journals
TNF inhibitor treatment models promote personalized care in ankylosing spondylitis
A retrospective cohort study of 10 randomized, controlled trials showed the ability of baseline variables to predict response to tumor necrosis...
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.